PD-L1 expression may elevate in a subset of metastatic clear cell renal cell carcinoma patients who are resistant to VEGFR-TKI, potentially through the mammalian target of rapamycin pathway (65). This evidence concerns the gene CD274 and clear cell renal carcinoma.